Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
Objective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four group...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-02-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htm |
_version_ | 1831765861128470528 |
---|---|
author | SI Yiran YUE Jian LIU Zhaoyang LI Mo ZHENG Yuanyi WANG Xiaobing YUAN Peng |
author_facet | SI Yiran YUE Jian LIU Zhaoyang LI Mo ZHENG Yuanyi WANG Xiaobing YUAN Peng |
author_sort | SI Yiran |
collection | DOAJ |
description | Objective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four groups which were immunized with PBS, IL-2, TCL and TCL+IL-2 for three weeks, and contra lateral tumors were implanted in the fourth week. We observed onset time of tumor and tumor size, collected peripheral blood continuously and monitored the expression of CD4+T and CD8+T cell subsets dynamically by flow cytometry. Spleen and tumor tissues of mice were also tested for CD4+T and CD8+T cell subsets by flow cytometry and immunohistochemistry, respectively. Results The preventive immunization of the TCL+IL-2 group significantly delayed the onset time of tumor (P=0.034); moreover, the tumor volume (P=0.023) and tumor weight (P=0.0015) were also significantly smaller than those in the control group. The expression of CD8+T cell subsets in the TCL+IL-2 group and the TCL-only group were significantly higher than that in the control group (P=0.0016, P=0.012). However, the CD4+T cell subsets of the TCL+IL-2 group decreased after tumor implantation, compared with the control group (P=0.0089). The expression of CD4+T and CD8+T cell subsets in spleen and tumor tissues were as same as those in peripheral blood. Conclusion The tumor vaccine of TCL combined with IL-2 could prevent the occurrence of melanoma in mouse and effectively inhibit tumor growth by activating CD8+T cells. |
first_indexed | 2024-12-22T06:11:47Z |
format | Article |
id | doaj.art-c868d319a80743dd968b4eddc7f6df2f |
institution | Directory Open Access Journal |
issn | 1000-8578 1000-8578 |
language | zho |
last_indexed | 2024-12-22T06:11:47Z |
publishDate | 2021-02-01 |
publisher | Magazine House of Cancer Research on Prevention and Treatment |
record_format | Article |
series | Zhongliu Fangzhi Yanjiu |
spelling | doaj.art-c868d319a80743dd968b4eddc7f6df2f2022-12-21T18:36:14ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782021-02-0148211512010.3971/j.issn.1000-8578.2021.20.06068578.2021.20.0606Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor GrowthSI Yiran0YUE Jian1LIU Zhaoyang2LI Mo3ZHENG Yuanyi4WANG Xiaobing5YUAN Peng6National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Ultrasound Medicine, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaObjective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four groups which were immunized with PBS, IL-2, TCL and TCL+IL-2 for three weeks, and contra lateral tumors were implanted in the fourth week. We observed onset time of tumor and tumor size, collected peripheral blood continuously and monitored the expression of CD4+T and CD8+T cell subsets dynamically by flow cytometry. Spleen and tumor tissues of mice were also tested for CD4+T and CD8+T cell subsets by flow cytometry and immunohistochemistry, respectively. Results The preventive immunization of the TCL+IL-2 group significantly delayed the onset time of tumor (P=0.034); moreover, the tumor volume (P=0.023) and tumor weight (P=0.0015) were also significantly smaller than those in the control group. The expression of CD8+T cell subsets in the TCL+IL-2 group and the TCL-only group were significantly higher than that in the control group (P=0.0016, P=0.012). However, the CD4+T cell subsets of the TCL+IL-2 group decreased after tumor implantation, compared with the control group (P=0.0089). The expression of CD4+T and CD8+T cell subsets in spleen and tumor tissues were as same as those in peripheral blood. Conclusion The tumor vaccine of TCL combined with IL-2 could prevent the occurrence of melanoma in mouse and effectively inhibit tumor growth by activating CD8+T cells.http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htmtumor cell lysateil-2melanomapreventiontherapy |
spellingShingle | SI Yiran YUE Jian LIU Zhaoyang LI Mo ZHENG Yuanyi WANG Xiaobing YUAN Peng Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth Zhongliu Fangzhi Yanjiu tumor cell lysate il-2 melanoma prevention therapy |
title | Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth |
title_full | Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth |
title_fullStr | Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth |
title_full_unstemmed | Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth |
title_short | Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth |
title_sort | immune mechanism of tumor cell lysate combined with il 2 preventing melanoma and inhibiting tumor growth |
topic | tumor cell lysate il-2 melanoma prevention therapy |
url | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htm |
work_keys_str_mv | AT siyiran immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT yuejian immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT liuzhaoyang immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT limo immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT zhengyuanyi immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT wangxiaobing immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth AT yuanpeng immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth |